FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic

[In The News]

SILVER SPRING, Md., March 5, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration today approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines but have not...

View the full article